Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), announced today updated results from an ongoing, multicenter, Phase 1/2 clinical trial examining the safety and efficacy of oral sapacitabine, the Company's lead product candidate, administered sequentially with decitabine. The study enrolled 25 patients aged 70 years or older, 76% of which were aged 75 years or older. Thirty-day mortality from all causes was 4% and 60-day mortality from all causes 12%.

The overall response rate was 40%. Median overall survival is 231 days and 44% of patients are still alive. The data were reported during a poster session at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego, California.